A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)

• Phase: Phase 3

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Treatments: Thyrotropin-Releasing Hormone

Criteria

Inclusion Criteria:

• Japanese SCD patients with ataxia (Experience of clinical trials of KPS-0373)

Exclusion Criteria:

• Patients with secondary ataxia

• Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

• Discontinuations in another clinical trials caused by side effects